Of note, Sample 02 was found to carry another TET2 variant—the p.Tyr1631* stopgain, reported as pathogenic in the COSMIC database and previously identified in angioimmunoblastic T cell lymphoma [33], CML, and AML [34] at a VAF of 1.4% (Table 2). The gene discussed is TET2; the disease is acute myeloid leukemia.